Phase 4 N=173 Neurocognitive and Metabolic Effects of Mild Hypothyroidism
Hypothyroidism
Primary: Executive Function — 7.9; 7.5; 8.8 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=11 Hypothyroidism Treated With Calcitonin
Hypothyroidism
Primary: Modified City of Hope Quality of Life Questionnaire for Patients With Thyroid Disease — -36.33 score on a scale
N/A N=14 Mechanistic Study of Subclinical Hypothyroidism In the Elderly
Subclinical Hypothyroidism
Primary: TSH Area Under the Curve — 267.8; 266.2 μIU*min/mL
N/A N=90 FGF-21 Levels and RMR in Children and Adolescents With Hashimoto's Thyroiditis (THYROMETABOL)
Hashimoto Disease
Primary: Fibroblast Growth Factor 21 (FGF-21) — 182.71; 217.36; 198.43 pg/mL
Phase 3 N=1,203 Thyroid Therapy for Mild Thyroid Deficiency in Pregnancy
Subclinical Hypothyroidism · Hypothyroxinemia · Pregnancy
Primary: Intellectual Function of Children at 5 Years of Age in Women Diagnosed With a) Subclinical Hypothyroidism or b) Hypothyroxinemia During the First Half of Pregnancy, or…
Phase 3 N=61 Early Levothyroxine Post Radioactive Iodine
Graves' Disease
Primary: Number of Participants With Overt Hypothyroidism — 11; 17 Participants — p=0.23
Phase 3 N=70 Role of Levothyroxine Supplementation in Delayed Recovery Following Cardiac Surgery
Cardiac Surgery Intensive Care Treatment · Delayed Recovery From Anaesthesia · Euthyroid Sick Syndrome
Primary: Change in Glasgow Coma Scale (GCS) From Intervention Initiation to ICU Discharge (Δ) — 6.65; 2.69 Score on a scale
N/A N=12 Treatment Trial of Subclinical Hypothyroidism in Down Syndrome
Down Syndrome · Subclinical Hypothyroidism
Primary: Change in Lipid Panel From Baseline at 6, 12 and 18 Months. — 160; 170; 163; 172 mg/dL
Phase 2 N=14 Thyroid and Glucose and Energy Metabolism
Thyroid Diseases
Primary: Insulin-mediated Glucose Disposal Rate at Levothyroxine Treatment Phase — 7.26 mg/kg/min
Phase 2 N=13 Energy Metabolism in Thyroidectomized Patients
Thyroid Goiter · Hypothyroidism · Thyroid Cancer
Primary: Short Term Change in Weight — 1.7; -0.76 Kilogram
Phase 2 N=46 Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism
Hypothyroidism
Primary: Dose Conversion Factor — 4.24 Ratio
N/A N=843 Observational Study on Hypothyroidism in Young Children Following Iodine Contrast Exposure
Hypothyroidism
Primary: Number of Pediatric Patients With Detected Hypothyroidism After Iodinated Contrast Exposure in a Routine Clinical Practice Setting — 11 Participants
N/A N=68 Targeted Levothyroxine Dosing in Infants With Congenital Hypothyroidism
Congenital Hypothyroidism
Primary: Dose Adjustments — 2.5; 2.4 Number of dose adjustments
N/A N=48 Thyroid Hormone Dose Adjustment in Pregnancy
Pregnancy · Hypothyroidism
Primary: Proportion of Patients in Each Treatment Arm Euthyroid Through Gestation — 24; 21 participants
N/A N=2,320 Iodinated Contrast Agents and Risk of Hypothyroidism in Young Children in the United States
Hypothyroidism
Primary: Incidence Rate of Hypothyroidism Detected in Routine Clinical Practice — 15.9 events per 1,000 person years
Phase 2 N=7 Thyroid Hormone to Induce Non-Insulin Mediated Glucose Disposal in People With Insulin Receptor Mutations
Insulin Resistance · Diabetes Mellitus · Abnormal Glucose Metabolism
Primary: Total Body Glucose Disposal in the Fasting State — 21.47 μmol/kg LBM (Lean Body Mass)/min
Phase 4 N=15 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury
Growth Hormone Deficiency · Traumatic Brain Injury
Primary: Maximum Oxygen Uptake at Baseline. — 29.0 mL/kg/min
Phase 2 N=25 Oral Testosterone for the Treatment of Hypogonadism in Males
Hypogonadism
Primary: Percentage of Responders — 67; 57; 50; 100 percentage of subjects
Phase 2 N=284 A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants
Hypothyroidism · Thyroid Disease · Euthyroid
Primary: Percentage of Participants With a Sustained TSH Response — 60.76; 75.92 percentage of participants
Phase 4 N=66 Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors
Hypothyroidism;Postablative
Primary: Thyroid Stimulating Hormone (TSH) — -0.676 mIU/L — p=<0.0001
Phase 4 N=30 Preoperative Steroids in Autoimmune Thyroid Disease
Thyroid Diseases
Primary: Thyroid Difficulty Scale Score — 9.8; 9.75 score on a scale
N/A N=34 Generic vs. Name-Brand Levothyroxine
Congenital Hypothyroidism · Hypothyroidism
Primary: Thyroid Stimulating Hormone as Primary Endpoint Measured at Initiation of Study, After 8 Weeks of One Drug, and Then 8 Weeks After the Second Drug. — 2.455; 2.131…
N/A N=21 Hypoglycemia and the Mineralocorticoid Receptor
Hypoglycemia
Primary: Change From Baseline in Cardiovascular Autonomic Function — -16.00; -16.59 ms/mmHg
Phase 3 N=68 Bone Properties in Hypoparathyroidism: Effects of PTH
Hypoparathyroidism
Primary: Requirements for Calcium Supplementation — 3.03; 1.66 grams per day of calcium supplementation
N/A N=93 Bone Structure and Strength Evaluated by Extreme-CT Scan Before and After Treatment of Hyper- and Hypothyroidism
Hyperthyroidism · Hypothyroidism
Primary: Thyroid Extreme CT — 0.89; 1.16 mm
Phase 4 N=50 Discontinuation of Levothyroxine Therapy for Patients With Subclinical Hypothyroidism
Subclinical Hypothyroidism
Primary: Participants' Willingness to Enter the Trial — 52 Participants
Phase 4 N=20 Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia
Growth Hormone Deficiency · Septo-Optic Dysplasia · Hypopituitarism
Primary: Change in Anthropometric Measures Over Time — 1.97; -0.61; 1.39; 1.22 Z-score
Phase 4 N=68 Effects of N-acetylcysteine on Low T3 Syndrome
Acute Myocardial Infarction · Euthyroid Sick Syndrome · Ischemic Heart Disease
Primary: Serum T3 Levels at 48 Hours — 93.5; 96.5 ng/dL
Phase 4 N=93 A Study to Learn if Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Can Improve Symptoms and Metabolic Control in Adults With Hypoparathyroidism (BALANCE)
Hypoparathyroidism
Primary: Change From Baseline in Hypoparathyroidism Symptom Diary (HypoPT-SD) Symptom Subscale Score at Week 26 — -0.93; -1.46 score on a scale — p==0.003
Phase 1 N=15 Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study
Multiple Sclerosis
Primary: Determine the Maximum Tolerated Dose (MTD) of Oral L-T3 in Subjects With MS — 75 mcg daily with BID dosing